Publications and presentations
AVEO Oncology allows you to access a number of published papers and presentations outlining our clinical data that were given at premier conferences and symposia around the world.
Antitumor Activity and Safety of Tivozanib (AV-951) in a Phase II Randomized Discontinuation Trial in Patients With Renal Cell Carcinoma
Authors: Dmitry A. Nosov, Brooke Esteves, Oleg N. Lipatov, Alexei A. Lyulko, A. A. Anischenko, Raju T. Chacko, Dinesh C. Doval, Andrew Strahs, William J. Slichenmyer, Pankaj Bhargava. Click here for link to article.
AACR 2012: The Effect of Food on the Pharmacokinetics of Tivozanib
AACR-NCI-EORTC 2011: A Phase I QTc Study of Tivozanib in Patients with Advanced Solid Tumors
Biological and Clinical Activity of Tivozanib, a Selective Inhibitor of VEGF Receptor-1, -2, and -3 Tyrosine Kinases, in a 4 Week on, 2 Week off Schedule in Patients With Advanced Solid Tumors.
Authors: Ferry A. L. M. Eskens, Maja J. A. de Jonge, Pankaj Bhargava, Toshiyuki Isoe, Monette M. Cotreau, Brooke Esteves, Kunihiko Hayashi, Herman Burger, Maarten Thomeer, Leni van Doorn, Jaap Verweij. Click here for link to article.